Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Navamedic ASA: NOTIFICATION OF MAJOR HOLDINGS | - | Oslo Børs | ||
Di | Navamedic ASA: Flaggemelding NAVA | - | Oslo Børs | ||
Mo | Navamedic ASA - New share capital registered | 3 | Cision News | ||
07.10. | Navamedic ASA: Notification of major shareholding | - | Oslo Børs | ||
07.10. | Navamedic ASA: Allocation of shares in the rights issue to primary insiders and their close associates | 2 | Cision News | ||
NAVAMEDIC Aktie jetzt für 0€ handeln | |||||
07.10. | Navamedic ASA: Final results of the rights issue | - | Oslo Børs | ||
06.10. | Navamedic ASA: Preliminary results of the rights issue | 2 | Cision News | ||
06.10. | Navamedic ASA: Last day of the subscription period in the rights issue | 1 | Cision News | ||
30.09. | Navamedic ASA: Last day of trading in subscription rights | 1 | Cision News | ||
22.09. | Navamedic ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates | 2 | Cision News | ||
22.09. | Navamedic ASA: Commencement of the subscription period for the rights issue | 1 | Cision News | ||
19.09. | Navamedic ASA: Approval and publication of prospectus | 1 | Cision News | ||
01.09. | Navamedic ASA: Updated key information relating to the rights issue | - | Oslo Børs | ||
14.08. | Navamedic Slips To Loss In Q2 | - | RTTNews | ||
14.08. | Navamedic ASA: Financial report for the 2nd quarter and first half of 2025 | 259 | PR Newswire | OSLO, Norway, Aug. 14, 2025 /PRNewswire/ -- In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health... ► Artikel lesen | |
14.08. | Navamedic Q2 2025 presentation: Underlying growth amid strategic acquisitions | 3 | Investing.com | ||
13.08. | Navamedic ASA: National approvals of Flexilev in OraFID granted across all Nordic countries | 267 | PR Newswire | OSLO, Norway, Aug. 13, 2025 /PRNewswire/ -- Navamedic is pleased to announce that it has received final approval for the packaging material in national languages for Norway, Sweden and Denmark... ► Artikel lesen | |
13.08. | Navamedic ASA: National approvals of Flexilev in OraFID granted across all Nordic countries. | 2 | Oslo Børs | ||
11.08. | Navamedic ASA: Invitation to 2025 2nd quarter presentation | 1 | Cision News | ||
16.07. | Navamedic completes dne pharma acquisition | 1 | Pharmaceutical Technology |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
DERMAPHARM | 32,950 | +0,76 % | Kurs der Dermapharm-Aktie verharrt auf Vortags-Niveau (31,85 €) | Der Kurs der der Dermapharm-Aktie kommt kaum von der Stelle. Der jüngste Kurs betrug 31,85 Euro. Ein geringes Minus von 0,78 Prozent zeigt die Kurstafel für der Anteilsschein von Dermapharm an. Die... ► Artikel lesen | |
HAPPY BELLY FOOD GROUP | 1,010 | +14,77 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces New Franchise Agreement and Real Estate Secured for Heal Wellness in Airdrie, Alberta | Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
CANTOURAGE GROUP | 3,270 | +4,14 % | EQS-News: Cantourage Group SE: Kabinettsbeschluss zum Medizinal-Cannabisgesetz trifft auf breites Unverständnis / Cantourage erwartet Anpassungen und bereitet Ausbau der eigenen Plattform "Telecan" vor | EQS-News: Cantourage Group SE
/ Schlagwort(e): Marktbericht
Kabinettsbeschluss zum Medizinal-Cannabisgesetz trifft auf breites Unverständnis / Cantourage erwartet Anpassungen... ► Artikel lesen | |
ZEALAND PHARMA | 64,76 | +0,43 % | Zealand Pharma A/S - admittance to trading and official listing of new shares due to exercise of employee warrants | The share capital of Zealand Pharma has been increased. The admittance to trading and official listing of new shares will take effect as of 16 September 2025 in the ISIN below.
ISIN:
DK0060257814
Name:
Zealand... ► Artikel lesen | |
BACHEM | 60,70 | -0,08 % | Bachem Holding AG: Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role | Bubendorf, Switzerland--(Newsfile Corp. - August 20, 2025) - The Bachem Group (SIX: BANB) announced today that Hans Van Hees, currently Chief Operations Officer Europe, will take on the role of... ► Artikel lesen | |
PHARMASGP | 31,400 | 0,00 % | HV-Termine: Hauptversammlungen bei Advanced Blockchain, Ceotronics, Haier, net digital, PharmaSGP, Varengold, Weng Fine Art | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
APONTIS PHARMA | 10,800 | 0,00 % | EQS-News: APONTIS PHARMA AG: Veränderungen im Vorstand | EQS-News: APONTIS PHARMA AG
/ Schlagwort(e): Personalie
APONTIS PHARMA: Veränderungen im Vorstand
20.08.2025 / 16:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
POLYPEPTIDE GROUP | 25,800 | -1,53 % | PolyPeptide Group: PolyPeptide Group achieves significant milestone in Malmö expansion project | PolyPeptide Group
/ Key word(s): Expansion
PolyPeptide Group achieves significant milestone in Malmö expansion project
22.09.2025 / 07:00 CET/CEST
Media Release
PolyPeptide... ► Artikel lesen | |
PHOTOCURE | 4,535 | 0,00 % | Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy | OSLO, Norway, Oct. 15, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation... ► Artikel lesen | |
ARCTICZYMES TECHNOLOGIES | 2,370 | -4,05 % | ArcticZymes Technologies ASA: ArcticZymes Technologies to present at the Pareto Securities 16th Healthcare Conference | ||
ZELLUNA | 0,902 | -6,82 % | Zelluna ASA: Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK | On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust... ► Artikel lesen | |
AQUA BIO TECHNOLOGY | 0,032 | -4,76 % | Aqua Bio Technology ASA: Correction: Aqua Bio Technology: Notice of extraordinary general meeting | ||
VISTIN PHARMA | 1,885 | -1,82 % | Vistin Pharma ASA: Second quarter and YTD 2025 financial results | Oslo, Norway, 15th of August 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK... ► Artikel lesen | |
BAYER | 27,255 | -0,27 % | Rekordhoch! Dax lässt nichts anbrennen: Bayer - Lage bleibt prekär, aber | Der Dax lässt im heutigen Donnerstagshandel (09. Oktober) nichts anbrennen. Der deutsche Leitindex markierte bereits im frühen Handel ein neues Rekordhoch. Bläst der Index womöglich schon zur vorgezogenen... ► Artikel lesen | |
MERCK KGAA | 116,45 | +0,95 % | Merck KGaA kauft in der Laborsparte zu | DARMSTADT (dpa-AFX) - Der Dax -Konzern Merck KGaA verstärkt sich in seiner Laborsparte und übernimmt das Chromatographie-Geschäft des US-amerikanischen Anbieters JSR Life Sciences. Beide Unternehmen... ► Artikel lesen |